The British Medical Association has dropped its opposition to the Cass Review and indicated it will accept the review as a basis for NHS gender healthcare policy. I want to be plain about what this is: it is not a routine professional update, it is not a considered response to new evidence, and it is not a neutral procedural step. It is a political act, and trans people waiting for care will pay the price.
Why the Cass Review cannot bear the weight being placed on it
The Cass Review has been systematically criticised by clinicians and researchers internationally, not because its critics disagree with its conclusions on ideological grounds, but because its methodology does not support those conclusions. The review excluded studies using evidence standards it did not apply to other sources. Work cited approvingly by the review has links to SEGM, the Society for Evidence-Based Gender Medicine, a network whose output functions as gatekeeping advocacy rather than independent research. The review's own evidence map acknowledged the weakness of the evidence base, yet its policy recommendations went far beyond what that evidence could justify.
Multiple countries and professional bodies have looked at the same international literature and reached different conclusions. The Swedish, Finnish, and Danish reviews that are sometimes cited alongside Cass as parallel caution actually recommended targeted, individualised access to care, not the near-total service closure that has followed in England. The World Professional Association for Transgender Health Standards of Care 8, the Endocrine Society guidelines, and UCSF's Pediatric Gender Affirming Care guidelines all continue to support access to gender-affirming care for young people with appropriate clinical involvement. The BMA is now aligning itself with the outlier position, not the consensus.
What this means for people waiting
NHS waiting lists for gender care in England run to years. Not months. Years. Young people referred to the new regional hubs created after the Cass Review are waiting so long that many will age out of paediatric services before they are ever seen. Adults referred to gender clinics are waiting so long that their mental health deteriorates, their relationships are strained, and their working lives are disrupted in ways that compound over time.
When a major professional body accepts the framework that justified this situation, it does not make the situation better. It makes it harder to challenge. It signals to commissioners, to politicians, and to tribunals that the restriction of care has professional backing. Every trans person who cannot access hormones, who cannot access psychological support, who cannot access a gender specialist, is affected by that signal.
The BMA's stated reasoning does not hold
The BMA has suggested this move reflects a concern for evidence-based medicine. Evidence-based medicine requires appraising the quality of evidence and the direction of the evidence base as a whole, not deferring to a single commissioned review whose methodology has been questioned by the very field it surveyed. Genuinely evidence-based medicine would look at the Endocrine Society's decades of clinical experience with gender-affirming hormones, the long-term follow-up studies from the Netherlands showing improved outcomes for young people who received care, and the consistent finding across the literature that withholding care is not without its own harms.
Delay is not neutral. Refusing to prescribe puberty blockers to a young person experiencing significant distress has consequences. Refusing hormones to an adult who has been waiting five years has consequences. Those consequences include worsening mental health, unwanted physical changes that cannot be reversed, and, at the extreme end, loss of life. An organisation that treats withholding care as the safe default is not applying evidential caution. It is making a choice about whose wellbeing counts.
What I want doctors to understand
If you are a doctor reading this and wondering whether the BMA's position gives you cover to step back from your trans patients, please think again. The General Medical Council's duties have not changed. Informed consent remains the foundation of good medical care. A patient in front of you with a clear need does not become less deserving of care because a professional body has softened its resistance to a contested review.
Trans people have always found ways to access care when the official system has failed them, through private providers, through community networks, through self-medication, and through sheer persistence. That is a scandal, not a solution. The BMA had an opportunity to say so clearly. It did not take it.
If this is useful to you, please share it. Every share helps more people find accurate information about gender diversity.
Dr Helen Webberley, Gender Specialist and Medical Educator.
helenwebberley.com